Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
Copper Quest Announces 2026 Exploration Programs Beginning with Drilling on the Rip Copper-Molybdenum Project
SAGA Metals Reports Assays from R-0024 to R-0026 with Intercepts Including 54.20% Fe2O3, 7.07% TiO2, 0.443% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
